pfizer director appointed to pyc

why would someone with such a massive reputation want to join the PYC board.....mmm this is now looking interesting.


FORMER PFIZER VICE-PRESIDENT OF CLINICAL RESEARCH JOINS
PHYLOGICA BOARD
Perth, 21 February 2007
Phylogica Limited (ASX:PYC) announced today that Dr Mark Pierce M.D. Ph.D., the
former Senior Vice President of Clinical Research at Pfizer, Inc. (the world’s largest
pharmaceutical company with revenues over US$50 billion), had been appointed as a
non-executive Director of Phylogica.
Dr Pierce, who serves on a number of biotechnology company boards, has a
distinguished career in the pharmaceutical industry.
He graduated from Northwestern University Medical School in Chicago and received
his postgraduate training in internal medicine at the Peter Bent Brigham Hospital and
Massachusetts General Hospital in Boston. Subsequently, he was Senior Vice
President of Clinical Research at Pfizer, after directing clinical development at Abbott
Laboratories and Warner Lambert Company.
“Dr Pierce brings a wealth of international drug development experience and major
pharmaceutical industry networks to Phylogica. This will open new doors to
pharmaceutical company clients for our drugs and technology and add significant
momentum to realising the value of Phylogica. ” said Phylogica CEO, Dr Stewart
Washer. “We are confident Dr Pierce’s experience and contacts will be invaluable at
this critical expansion stage as Phylogica continues to develop new relationships with
international biotechnology and pharmaceutical companies and expand on our current
deals with Opsona Therapeutics and Johnson & Johnson Research,” added Dr
Washer.
“I am delighted to have been asked to join the Phylogica Board of Directors, “ said Dr
Pierce. “The company has a world-class drug discovery engine that has been validated
by the commercialisation deals it has consummated so far, and I look forward to
contributing to the future development of the company, its technology and its
products,” added Dr Pierce.